- Bedwetting is a complex disorder involving several factors such as bladder dysfunction, the inability to wake up and an over-production of urine at night1 and will not necessarily go away by itself2
- An increased association between bedwetting, brain and psychological functioning as well as sleep issues is well documented1,3
- Successfully treating bedwetting removes the emotional burden placed on the child, and has shown to improve auditory work memory, quality of life and day time functioning4
- Bedwetting is nobody’s fault; it is a common medical condition that can and should be treated5
Evotec Extends Integrated Drug Discovery Alliance with Genentech
HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics. The collaboration initiated in May 2010 was renewed in 2013 and this second extension further validates the value of Evotec’s state-of-the-art technology platform and broad expertise in drug discovery. Activities performed within the collaboration include pharmacology, screening, chemistry, proteomics and structural biology.
New Study Shows Female Cancer Survivors Need More Fertility Counseling
MANHASSET , NY – Despite expressing concerns about their ability to bear children in the future, many young adult females who survive cancer do not receive enough information about their fertility as part of their survivorship care, according to a new study by researchers at Northwell Health’s Feinstein Institute for Medical Research and Memorial Sloan Kettering Cancer Center. read more
NCCN Receives Funding for Policy and Advocacy Fellow
Through funding from EMD Serono, NCCN is instituting a Policy and Advocacy Fellowship designed for implementation of policy programs that will enhance access to and delivery of quality oncology care in the United States and globally.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network ® ( NCCN ® ) is instituting a new Policy and Advocacy Fellowship to support access to and delivery of high-quality cancer care worldwide as part of its Oncology Policy Program. The two-year Fellowship is made possible through funding from EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany in the United States and Canada. read more
Allergan’s BOTOX Vista® (botulinum toxin type A) Receives National Marketing Authorisation in Japan for Treatment of Crow’s Feet Lines in Adult Patients
DUBLIN, May 23, 2016 /PRNewswire/ –Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista® (Allergan’s botulinum toxin type A product) as a treatment for crow’s feet lines (CFL).3 BOTOX Vista® is now indicated for the temporary improvement in the appearance of lateral canthal lines (CFL) in adult patients under the age of 65.3 This marketing authorisation is specific to Allergan’s botulinum toxin type A product.
Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases
CHIPPENHAM, United Kingdom and MADISON, Wis., May 24, 2016 /PRNewswire/ — Vectura Group plc (LSE: VEC) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura’s proven dry powder inhaler (“DPI”) technology with Propeller’s FDA-cleared digital health platform. read more
Interventional Spine, Inc. announces FDA Clearance of Lordotic Opticage
PRNewswire/ — Interventional Spine, Inc. announced today FDA clearance of its 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device. This device joins the Interventional Spine family of Opticage™ Expandable Interbody Fusion Devices previously cleared late last year, and also used with the Company’s PerX360 System™. The Lordotic 80 Opticage™ is a lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1.
Targeted treatment for liver cancer under way
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer. The findings were published in Nature Medicine .
The study found that mouse and human liver cancer in which the function of the protein p53 is disturbed or inhibited is dependent on the interaction between the Aurora kinase A (AURKA) and MYC proteins. Interfering the AURKA protein with a specific drug molecule inhibits this interaction and causes cancer cells to die. read more